| The excessive tonic inhibition of the peri-infarct cortex depresses low gamma rhythm-power during post-stroke recovery M Alasoadura, J Leclerc, M Hazime, J Leprince, D Vaudry, J Chuquet JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM 42 (1_ SUPPL), 206-206, 2022 | | 2022 |
| Concentration dependent dual effect of the endozepine ODN on neuronal spiking activity M Hazime, M Gasselin, M Alasoadura, D Lanfray, J Leclerc, B Lefranc, ... bioRxiv, 2022.04. 05.487159, 2022 | | 2022 |
| Vascular response to spreading depolarization predicts stroke outcome NF Binder, C Glück, W Middleham, M Alasoadura, N Pranculeviciute, ... Stroke 53 (4), 1386-1395, 2022 | 16 | 2022 |
| The gliopeptide ODN, a ligand for the benzodiazepine site of GABAA receptors, boosts functional recovery after stroke R Lamtahri, M Hazime, EK Gowing, RY Nagaraja, J Maucotel, ... Journal of Neuroscience 41 (33), 7148-7159, 2021 | 11 | 2021 |
| Point-Substitution of Phenylalanine Residues of 26RFa Neuropeptide: A Structure-Activity Relationship Study B Lefranc, K Alim, C Neveu, O Le Marec, C Dubessy, JA Boutin, ... Molecules 26 (14), 4312, 2021 | 4 | 2021 |
| Prolonged deficit of low gamma oscillations in the peri-infarct cortex of mice after stroke M Hazime, M Alasoadura, R Lamtahri, P Quilichini, J Leprince, D Vaudry, ... Experimental Neurology 341, 113696, 2021 | 12 | 2021 |
| Cytoprotective and Neurotrophic Effects of Octadecaneuropeptide (ODN) in in vitro and in vivo Models of Neurodegenerative Diseases O Masmoudi-Kouki, A Namsi, Y Hamdi, S Bahdoudi, I Ghouili, J Chuquet, ... Frontiers in Endocrinology 11, 566026, 2020 | 5 | 2020 |
| Endozepines and their receptors: structure, functions and pathophysiological significance MC Tonon, H Vaudry, J Chuquet, F Guillebaud, J Fan, O Masmoudi-Kouki, ... Pharmacology & therapeutics 208, 107386, 2020 | 62 | 2020 |
| Spatio-temporal evolution of neural oscillations power in the recovering cortex after stroke J Chuquet, M Hazime, M Alasoadura, P Quilichini, J Leprince, D Vaudry JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM 39, 392-392, 2019 | | 2019 |
| Intranasal Administration of Diazepam-binding Inhibitor Derived Peptides for Brain Delivery D Lanfray, B Lefranc, H Vaudry, J Chuquet, D Vaudry, V Prevot, ... | | 2018 |
| Design, synthesis, molecular dynamics simulation, and functional evaluation of a novel series of 26RFa peptide analogues containing a mono-or polyalkyl guanidino arginine … K Alim, B Lefranc, J Sopkova-de Oliveira Santos, C Dubessy, M Picot, ... Journal of Medicinal Chemistry 61 (22), 10185-10197, 2018 | 8 | 2018 |
| Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson’s disease S Bahdoudi, I Ghouili, M Hmiden, JL Do Rego, B Lefranc, J Leprince, ... Cellular and molecular life sciences 75, 2075-2091, 2018 | 16 | 2018 |
| Effect of human QRFPR ligands in the insulin tolerance test in mice. K Alim, B Lefranc, M Picot, G Prévost, J Chuquet, D Vaudry, H Vaudry, ... Peptides 2017, Proceedings of the 34th European Peptide Symposium. pp 127-128, 2017 | | 2017 |
| Caractérisation des effets de l'octadécaneuropeptide dans l'ischémie cérébrale chez la souris R Lamthari Rouen, 2016 | | 2016 |
| Demonstration of the occurrence of a non-transmembrane-helix in the extracellular loop 2 of GPR103 K Alim, L Guilhaudis, I Ségalas-Milazzo, D Vaudry, J Chuquet, R Bureau, ... Congrès du Groupe français des peptides et des protéines (GFPP, 19, 2015), 2015 | | 2015 |
| Detection, characterization and biological activities of [bisphospho-thr3, 9] ODN, an endogenous molecular form of ODN released by astrocytes K Gach, O Belkacemi, B Lefranc, P Perlikowski, J Masson, ... Neuroscience 290, 472-484, 2015 | 11 | 2015 |
| Molecular basis of agonist docking in a human GPR 103 homology model by site‐directed mutagenesis and structure–activity relationship studies C Neveu, F Dulin, B Lefranc, L Galas, C Calbrix, R Bureau, S Rault, ... British Journal of Pharmacology 171 (19), 4425-4439, 2014 | 17 | 2014 |
| COMPARTMENTALIZATION OF GLUCOSE UPTAKE BETWEEN ASTROCYTES AND NEURONS IN VIVO J Chuquet GLIA 61, S31-S31, 2013 | | 2013 |
| Rational Design of a Low Molecular Weight, Stable, Potent, and Long-Lasting GPR103 Aza-β3-pseudopeptide Agonist C Neveu, B Lefranc, O Tasseau, JC Do-Rego, A Bourmaud, P Chan, ... Journal of Medicinal Chemistry 55 (17), 7516-7524, 2012 | 34 | 2012 |
| Experimental characterization of an interaction between 26RFa and its receptor J Leprince, C Neveu, F Dulin, B Lefranc, J Santos, S de Oliveira, L Galas, ... JOURNAL OF PEPTIDE SCIENCE 18, S104-S105, 2012 | | 2012 |
David VaudryChercheur INSERM, Unité INSERM 982, Plates-Formes PRIMACEN et PISSARO, Université de Rouen在 univ-rouen.fr 的电子邮件经过验证
